For the HER2, the worldwide prevalence of its amplification in BCs ranges only between 15 and 30% while in other types of cancer, such as colorectal cancer, HER2 does not show a prognostic value (Kruszewski et al., 2010). This evidence concerns the gene ERBB2 and colorectal cancer.